Anti-TAF9抗体- ChIP Grade (ab30963)


  • 产品名称Anti-TAF9抗体- ChIP Grade
    参阅全部 TAF9 一抗
  • 描述
    兔多克隆抗体to TAF9 - ChIP Grade
  • 经测试应用适用于: ChIP, WB, ELISA, IHC-Pmore details
  • 种属反应性
    与反应: Human
    预测可用于: Mouse, Rat, Horse, Cow, Cat, Dog, Pig
  • 免疫原

    Synthetic peptide derived from residues 28 - 77 of human TAF9.


  • 阳性对照
    • WB: fetal small intestine lysate IHC: human skin




Our Abpromise guarantee covers the use of ab30963 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
ChIP Use at an assay dependent concentration.
WB Use a concentration of 0.125 µg/ml. Detects a band of approximately 20 kDa (predicted molecular weight: 29 kDa). Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.
ELISA 1/312500.
IHC-P Use at an assay dependent concentration.


  • 相关性TAF9 functions as a component of the DNA-binding general transcription factor complex TFIID and the regulatory transcription complex SAGA. Binding of TFIID to a promoter (with or without TATA element) is the initial step in pre-initiation complex (PIC) formation. TFIID plays a key role in the regulation of gene expression by RNA polymerase II through different activities such as transcription activator interaction, core promoter recognition and selectivity, TFIIA and TFIIB interaction, chromatin modification (histone acetylation by TAF1), facilitation of DNA opening and initiation of transcription. SAGA influences RNA polymerase II transcriptional activity through different activities such as TBP interaction (SPT3 and SPT8) and promoter selectivity, interaction with transcription activators (GCN5, ADA2, ADA3, and TRA1), and chromatin modification through histone acetylation (GCN5).
  • 细胞定位Nuclear
  • 数据库链接
  • 别名
    • TAF9 RNA polymerase II, TATA box-binding protein-associated factor, 32kDa antibody
    • MGC:1603 antibody
    • MGC:3647 antibody
    • MGC:5067 antibody
    • RNA polymerase II TBP-associated factor subunit G antibody
    • STAF31/32 antibody
    • TAF17 antibody
    • TAF2G antibody
    • TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32kDa antibody
    • TAFII31 antibody
    • TAFII32 antibody
    • TAFIID32 antibody
    • TATA box-binding protein-associated factor 2G antibody
    • TBP associated factor 17 kDa antibody
    • TBP associated factor 9 antibody
    • TBP associated factor, RNA polymerase II, 32-KD antibody
    • transcription initiation factor TFIID 31 kD subunit antibody
    • transcription initiation factor TFIID 31 kDa subunit antibody
    • transcription initiation factor TFIID 32 kDa subunit antibody
    • Transcription initiation factor TFIID subunit 9 antibody
    see all

Anti-TAF9 antibody - ChIP Grade 图像

  • Quiescent human colon carcinoma HCT116 cultures were treated with 10% FBS for three time points (0, 15, 30 minutes) or (0, 30, 60 minutes) were used in Matrix-ChIP and real-time PCR assays at EGR1 gene (Exon1) and 15kb upstream site.

  • Anti-TAF9 antibody - ChIP Grade (ab30963) at 0.125 µg/ml + Fetal small intestine lysate

    HRP conjugated anti-rabbit IgG

    Predicted band size : 29 kDa
    Observed band size : 15,20 kDa (why is the actual band size different from the predicted?)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human skin tissue labelling TAF9 with ab30963 at 4-8µg/ml.Positively labelled cells are indicated by arrows (squamous epthelial cells). Magnification: 40X.

Anti-TAF9 antibody - ChIP Grade (ab30963)参考文献

ab30963 has not yet been referenced specifically in any publications.

Product Wall

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 1.4% · Temperature: RT°C
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: pH 7
Sample Mouse Tissue sections (Testis)
Specification Testis
Permeabilization No
Fixative Formaldehyde

Abcam user community

Verified customer

提交于 Apr 30 2014